detected (Fig. 2a) in the first elution step, indicating the potential
of the LaGM probe for enriching low-abundance peptides from
real samples. More importantly, two labeled phosphopeptides are
successfully detected with a clean background in the second elution
step (Fig. 2b). The MALDI tandem mass spectrometry (MS/MS)
further confirms the effectiveness of the LaGM probe for capturing
and labeling the phosphopeptides (Fig. S12, ESIw). These results
demonstrate that the LaGM probe can be used for selective
capture, sequential MS detection and easy discrimination of
low-abundance peptides and phosphopeptides. For comparison,
two types of commercial affinity products (ZipTipC18 pipette tip
and TiO2 nanoparticles) were also used to capture target peptides
from diluted human serum under the same experimental conditions
(Fig. S10 and S11, ESIw). Obviously, the monofunctional
commercial products cannot be used for selective capture and
sequential determination of the corresponding biomolecules.
While the selectivity and the efficiency of commercial TiO2
nanoparticles for enrichment of phosphopeptides are inferior
to those of the LaGM probe.
Fig. 2 The MALDI-TOF mass spectra of the diluted human serum
solution: (a) the low-abundance peptides enriched by LaGM in the first
step, and (b) the labeled phosphopeptides captured by LaGM in the second
step. The number in the top right corner is the highest peak intensity.
analysis (Fig. S8a, ESIw) because of the nonphosphopeptide
suppression effect. However, after treatment with the LaGM probe,
three expected phosphopeptides with strong MS peak intensity are
detected (Fig. S8b, ESIw). Furthermore, these phosphopeptides can
be easily identified because a series of characteristic fragment ions of
mass loss of 80 Da (marked with ‘#’) are also observed. It should be
pointed out that the Fe3O4 nanoparticles also have corresponding
contribution to the capture of phosphopeptides. But then, their
contribution is far inferior to that of the LaPO4 nanorod based on
comparison of their MS intensities of phosphopeptides (Fig. S8c,
ESIw). To investigate the detection limit, the LaGM probe was
applied to capture phosphopeptides from the b-casein digest with
different concentrations. When the concentration is as low as
10ꢀ9 M, phosphopeptides can still be detected (Fig. S8d, ESIw).
A complex peptide mixture consisting of b-casein and BSA
(1 : 50 molar ratio) was further used to evaluate the selectivity
of the LaGM probe for capture of phosphopeptides. Appar-
ently, no phosphopeptides can be detected from the peptide
mixture due to the suppression effect and interference from the
abundant nonphosphopeptides (Fig. S9a, ESIw). However, after
selective capture using the affinity probe, three labeled phos-
phopeptides can be clearly identified in the mass spectrum and
free of the interference of nonphosphopeptide peaks (Fig. S9b,
ESIw). These results confirm that the LaGM probe can also be
used for selective capture of phosphopeptides.
In summary, a new graphene-based affinity probe consisting of
the graphene scaffold, affinity nanorods and magnetic nano-
particles has been synthesized. The multifunctional probe can be
used for selective capture, sequential determination and direct
identification of two types of peptides. This affinity probe has
better sensitivity and selectivity than the commercial ZipTipC18
pipette tip and TiO2 affinity product. Therefore, this work could
provide new insights for the design of the multifunctional
graphene-based affinity probes for extracting low-abundance
biomarkers from complex biosamples in biomedical application.
The work was supported by the Natural Science Founda-
tion of China (NSFC) (Grant No. 20871083 and 21171161).
Notes and references
1 A. Doerr, Nat. Methods, 2008, 5, 858; M. Swami, Nat. Rev. Cancer,
2010, 10, 597.
2 B. F. Cravatt, G. M. Simon and J. R. Yates III, Nature, 2007,
450, 991; Z. Lu, L. He and Y. Yin, Chem. Commun., 2010, 46, 6174.
3 H. Qin, P. Gao, F. Wang, L. Zhao, J. Zhu, A. Wang, T. Zhang,
R. a. Wu and H. Zou, Angew. Chem., Int. Ed., 2011, 50, 12218;
M. Gao, D. Qi, P. Zhang, C. Deng and X. Zhang, Expert Rev.
Proteomics, 2010, 7, 665.
4 G. Han, M. Ye and H. Zou, Analyst, 2008, 133, 1128.
5 H. Chen, C. Deng, Y. Li, Y. Dai, P. Yang and X. Zhang, Adv.
Mater., 2009, 21, 2200; H. Chen, X. Xu, N. Yao, C. Deng, P. Yang
and X. Zhang, Proteomics, 2008, 8, 2778.
6 Y. Li, J. Wu, D. Qi, X. Xu, C. Deng, P. Yang and X. Zhang, Chem.
Commun., 2008, 564.
7 T. E. Thingholm, T. J. Jorgensen, O. N. Jensen and M. R. Larsen,
Nat. Protocols, 2006, 1, 1929.
8 Y. Liu, J. Liu, C. Deng and X. Zhang, Rapid Commun. Mass
Spectrom., 2011, 25, 3223.
9 S. Guo and S. Dong, Chem. Soc. Rev., 2011, 40, 2644; Q. Liu, J. Shi,
J. Sun, T. Wang, L. Zeng and G. Jiang, Angew Chem., 2011, 123, 6035.
Human serum containing various informative endogenous
peptides including the phosphopeptides released by diseased tissue
and these peptides have gained considerable interest for the disease
biomarker discovery.13 To prove the practical effect of the LaGM
probe (as shown in Scheme 1b), human serum was used as a real
biosample for the selective enrichment of low-abundance peptides
and phosphopeptides, fast magnetic isolation, controllable elution
and sequential MS detection including direct identification of the
phosphopeptides.
10 S. W. Pettersson, B. S. Persson and M. Nystrom, J. Chromatogr.,
¨
B: Biomed. Appl., 2004, 803, 159; H. Chen, D. Qi, C. Deng,
P. Yang and X. Zhang, Proteomics, 2009, 9, 380.
11 H. Sun, L. Cao and L. Lu, Nano Res., 2011, 4, 550; Y. Zou and
Y. Wang, ACS Nano, 2011, 5, 8108.
Fig. S10a (ESIw) shows the mass spectra of the diluted human
serum before treatment using the affinity probe. No peptides can
be identified because the MS signals of peptides were severely
suppressed and disturbed by the salts and other contaminants in
serum. In contrast, after treatment with the LaGM probe, many
peptides with high MS peak intensity and S/N ratio can be easily
12 G. Cheng, J. L. Zhang, Y. L. Liu, D. H. Sun and J. Z. Ni, Chem.
Commun., 2011, 47, 5732; G. Cheng, J. L. Zhang, Y. L. Liu,
D. H. Sun and J. Z. Ni, Chem.–Eur. J., 2012, 18, 2014; G. Cheng,
Y.-L. Liu, J.-L. Zhang, D.-H. Sun and J.-Z. Ni, Anal. Bioanal.
Chem., 2012, 404, 763.
13 S. Hu, J. A. Loo and D. T. Wong, Proteomics, 2006, 6, 6326;
S. M. Hanash, S. J. Pitteri and V. M. Faca, Nature, 2008, 452, 571.
c
10242 Chem. Commun., 2012, 48, 10240–10242
This journal is The Royal Society of Chemistry 2012